Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Biogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Product- Rare Disease- SPINRAZA- United States: $204.3 million versus $149.18 million estimated by 22 analysts on average. Compared to the year-ago quarter, this number represents a +36.8% change.
• Revenue- Product- Multiple Sclerosis (MS)- United States: $621 million compared to the $573 million average estimate based on 21 analysts. The reported number represents a change of -5.5% year over year.
• Revenue- Product- Rare Disease- SKYCLARYS - United States: $82.3 million versus the 21-analyst average estimate of $84.27 million. The reported number represents a year-over-year change of +5.5%.
• Revenue- Product- Multiple Sclerosis (MS)- Interferon- United States: $146.1 million versus the 21-analyst average estimate of $138.46 million. The reported number represents a year-over-year change of -2.6%.
• Revenue- Anti-CD20 therapeutic programs: $513.5 million compared to the $473.33 million average estimate based on 25 analysts. The reported number represents a change of +9.9% year over year.
• Revenue- Contract manufacturing, royalty and other revenue: $242.4 million versus $151.82 million estimated by 23 analysts on average.
• Revenue- Product- Multiple Sclerosis (MS)- Fumarate- Total: $287.4 million compared to the $308.1 million average estimate based on 23 analysts. The reported number represents a change of -29.2% year over year.
• Alzheimer's collaboration revenue: $63.7 million versus $65.97 million estimated by 23 analysts on average. Compared to the year-ago quarter, this number represents a +16% change.
• Revenue- Product- Rare Disease- SKYCLARYS- Total: $167.9 million versus $154.66 million estimated by 23 analysts on average. Compared to the year-ago quarter, this number represents a +28.9% change.
• Revenue- Product- Rare Disease- SPINRAZA- Total: $401.9 million compared to the $379.46 million average estimate based on 23 analysts. The reported number represents a change of +2.3% year over year.
• Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Total: $450.8 million versus the 23-analyst average estimate of $374.73 million. The reported number represents a year-over-year change of -0.8%.
• Revenue- Product- Biosimilars- Total: $152.8 million versus the 22-analyst average estimate of $160.18 million. The reported number represents a year-over-year change of -15.9%.

View all Key Company Metrics for Biogen here>>>

Shares of Biogen have returned -4.8% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research